Daiwa Securities Group Inc. Raises Position in Zoetis Inc. (NYSE:ZTS)

Daiwa Securities Group Inc. grew its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 15.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,453 shares of the company's stock after acquiring an additional 9,451 shares during the period. Daiwa Securities Group Inc.'s holdings in Zoetis were worth $14,155,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of ZTS. Darwin Wealth Management LLC acquired a new stake in Zoetis in the third quarter valued at approximately $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis in the 3rd quarter valued at $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis in the 3rd quarter valued at $33,000. Quarry LP lifted its position in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company's stock worth $36,000 after purchasing an additional 153 shares during the last quarter. Finally, LRI Investments LLC acquired a new position in shares of Zoetis during the first quarter worth $43,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

Shares of Zoetis stock traded up $1.74 during trading on Monday, reaching $178.70. The company's stock had a trading volume of 4,558,329 shares, compared to its average volume of 2,551,175. The firm has a market cap of $80.62 billion, a PE ratio of 33.59, a P/E/G ratio of 2.71 and a beta of 0.90. The company has a 50-day moving average price of $185.31 and a two-hundred day moving average price of $180.79. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the business posted $1.36 earnings per share. Zoetis's quarterly revenue was up 11.6% on a year-over-year basis. On average, analysts forecast that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.97%. Zoetis's payout ratio is 32.52%.

Analyst Ratings Changes

A number of research firms have weighed in on ZTS. BTIG Research raised their price target on Zoetis from $220.00 to $225.00 and gave the company a "buy" rating in a research note on Monday, August 12th. Argus upgraded Zoetis to a "strong-buy" rating in a research note on Friday, August 9th. Piper Sandler upped their price target on Zoetis from $195.00 to $210.00 and gave the company an "overweight" rating in a report on Wednesday, August 14th. Stifel Nicolaus raised their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a "buy" rating in a report on Wednesday, September 18th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Zoetis has an average rating of "Buy" and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.